In this study, the encapsulation of curcumin (Cur) in "drug-in-cyclodextrin-in-liposomes (DCL)" by following the double-loading technique (DL) was proposed, giving rise to DCLâ»DL. The aim was to analyze the effect of cyclodextrin (CD) on the physicochemical, stability, and drug-release properties of liposomes. After selecting didodecyldimethylammonium bromide (DDAB) as the cationic lipid, DCLâ»DL was formulated by adding 2-hydroxypropyl-α/β/γ-CD (HPβCD)â»Cur complexes into the aqueous phase. A competitive effect of cholesterol (Cho) for the CD cavity was found, so cholesteryl hemisuccinate (Chems) was used. The optimal composition of the DCLâ»DL bilayer was obtained by applying Taguchi methodology and regression analysis. Vesicles showed a lower drug encapsulation efficiency compared to conventional liposomes (CL) and CL containing HPβCD in the aqueous phase. However, the presence of HPβCD significantly increased vesicle deformability and Cur antioxidant activity over time. In addition, drug release profiles showed a sustained release after an initial burst effect, fitting to the Korsmeyer-Peppas kinetic model. Moreover, a direct correlation between the area under the curve (AUC) of dissolution profiles and flexibility of liposomes was obtained. It can be concluded that these "drug-in-cyclodextrin-in-deformable" liposomes in the presence of HPβCD may be a promising carrier for increasing the entrapment efficiency and stability of Cur without compromising the integrity of the liposome bilayer.
Novel Findings about Double-Loaded Curcumin-in-HPβcyclodextrin-in Liposomes: Effects on the Lipid Bilayer and Drug Release.
阅读:5
作者:Fernández-Romero Ana-MarÃa, Maestrelli Francesca, Mura Paola Angela, Rabasco Antonio MarÃa, González-RodrÃguez MarÃa Luisa
| 期刊: | Pharmaceutics | 影响因子: | 5.500 |
| 时间: | 2018 | 起止号: | 2018 Dec 3; 10(4):256 |
| doi: | 10.3390/pharmaceutics10040256 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
